Clinical trial
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
NCT00709761
Study timeline
Study start (actual)2008-07-02Date precision: day
Registry last updated2019-03-26
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Neoplasms, Breastunresolved
Interventions
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Mapped research locations
New YorkNew York, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1ClevelandOhio, United States1CincinnatiOhio, United States1RochesterNew York, United States1RichmondVirginia, United States1Long BeachCalifornia, United States1TacomaWashington, United States1Fort MyersFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00709761 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.